Predictors of non-adherence to and non-persistence with statin therapy among patients on oral diabetes medication in the netherlands: A retrospective inception cohort study

Sofa Dewi Alfian; Pawida Worawutputtapong; Catharina C.M. Schuiling-Veninga; Jurjen Van Der Schans; JH Bos; Eelko Hak; Petra Denig

doi:10.1002/pds.4275

Abstract

Background: The use of statins as the most extensively used lipid-lowering therapy is known to be suboptimal in daily practice. Few studies, however, have looked at non-adherence and non-persistence as distinct phenomena. Objectives: To evaluate statin adherence and persistence rate, and to identify potential predictors associated with statin non-adherence and non-persistence among patients on oral diabetes medication. Methods: We conducted a cohort study of statin starters using the pharmacy database IADB.nl. We included patients on oral diabetes medication aged 40 years and older at the start of statin treatment between 1994 and 2014. Adherence and persistence rates were measured during a 3-year follow-up. Patients were considered non-persistent when there was a gap of ≥180 days after the end of a prescription. Adherence rates were calculated as the proportion of days covered (PDC) for persistent patients. Patients with a PDC

Original language	English
Article number	856
Pages (from-to)	517-518
Number of pages	2
Journal	Pharmacoepidemiology and Drug Safety
Volume	26
Issue number	Supplement 2
DOIs	https://doi.org/10.1002/pds.4275
Publication status	Published - 22-Aug-2017
Event	33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management - Montreal, Canada Duration: 25-Aug-2017 → 30-Aug-2017 https://www.pharmacoepi.org/meetings/33ICPE/

Keywords

hydroxymethylglutaryl coenzyme A reductase inhibitor
adult
aged
clinical trial
cohort analysis
diabetes mellitus
drug therapy
female
follow up
hazard ratio
human
major clinical study
male
middle aged
Netherlands
pharmacy
prescription
primary prevention
proportional hazards model
retrospective study
secondary prevention
social status
IADB

Access to Document

10.1002/pds.4275

AbstractsFinal publisher's version, 3.66 MBLicence: Taverne

Handle.net

Persistent link

Cite this

Alfian, S. D., Worawutputtapong, P., Schuiling-Veninga, C. C. M., Van Der Schans, J., Bos, JH., Hak, E., & Denig, P. (2017). Predictors of non-adherence to and non-persistence with statin therapy among patients on oral diabetes medication in the netherlands: A retrospective inception cohort study. Pharmacoepidemiology and Drug Safety, 26(Supplement 2), 517-518. Article 856. https://doi.org/10.1002/pds.4275

@article{6ed757f4de144f388f33234407ee2e31,

title = "Predictors of non-adherence to and non-persistence with statin therapy among patients on oral diabetes medication in the netherlands: A retrospective inception cohort study",

abstract = "Background: The use of statins as the most extensively used lipid-lowering therapy is known to be suboptimal in daily practice. Few studies, however, have looked at non-adherence and non-persistence as distinct phenomena. Objectives: To evaluate statin adherence and persistence rate, and to identify potential predictors associated with statin non-adherence and non-persistence among patients on oral diabetes medication. Methods: We conducted a cohort study of statin starters using the pharmacy database IADB.nl. We included patients on oral diabetes medication aged 40 years and older at the start of statin treatment between 1994 and 2014. Adherence and persistence rates were measured during a 3-year follow-up. Patients were considered non-persistent when there was a gap of ≥180 days after the end of a prescription. Adherence rates were calculated as the proportion of days covered (PDC) for persistent patients. Patients with a PDC",

keywords = "hydroxymethylglutaryl coenzyme A reductase inhibitor, adult, aged, clinical trial, cohort analysis, diabetes mellitus, drug therapy, female, follow up, hazard ratio, human, major clinical study, male, middle aged, Netherlands, pharmacy, prescription, primary prevention, proportional hazards model, retrospective study, secondary prevention, social status, IADB",

author = "Alfian, {Sofa Dewi} and Pawida Worawutputtapong and Schuiling-Veninga, {Catharina C.M.} and {Van Der Schans}, Jurjen and JH Bos and Eelko Hak and Petra Denig",

year = "2017",

month = aug,

day = "22",

doi = "10.1002/pds.4275",

language = "English",

volume = "26",

pages = "517--518",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

publisher = "Wiley",

number = "Supplement 2",

note = "33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management ; Conference date: 25-08-2017 Through 30-08-2017",

url = "https://www.pharmacoepi.org/meetings/33ICPE/",

}

Alfian, SD, Worawutputtapong, P, Schuiling-Veninga, CCM , Van Der Schans, J , Bos, JH , Hak, E & Denig, P 2017, 'Predictors of non-adherence to and non-persistence with statin therapy among patients on oral diabetes medication in the netherlands: A retrospective inception cohort study', Pharmacoepidemiology and Drug Safety, vol. 26, no. Supplement 2, 856, pp. 517-518. https://doi.org/10.1002/pds.4275

Predictors of non-adherence to and non-persistence with statin therapy among patients on oral diabetes medication in the netherlands: A retrospective inception cohort study. / Alfian, Sofa Dewi; Worawutputtapong, Pawida; Schuiling-Veninga, Catharina C.M. et al.
In: Pharmacoepidemiology and Drug Safety, Vol. 26, No. Supplement 2, 856, 22.08.2017, p. 517-518.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Predictors of non-adherence to and non-persistence with statin therapy among patients on oral diabetes medication in the netherlands: A retrospective inception cohort study

AU - Alfian, Sofa Dewi

AU - Worawutputtapong, Pawida

AU - Schuiling-Veninga, Catharina C.M.

AU - Van Der Schans, Jurjen

AU - Bos, JH

AU - Hak, Eelko

AU - Denig, Petra

PY - 2017/8/22

Y1 - 2017/8/22

N2 - Background: The use of statins as the most extensively used lipid-lowering therapy is known to be suboptimal in daily practice. Few studies, however, have looked at non-adherence and non-persistence as distinct phenomena. Objectives: To evaluate statin adherence and persistence rate, and to identify potential predictors associated with statin non-adherence and non-persistence among patients on oral diabetes medication. Methods: We conducted a cohort study of statin starters using the pharmacy database IADB.nl. We included patients on oral diabetes medication aged 40 years and older at the start of statin treatment between 1994 and 2014. Adherence and persistence rates were measured during a 3-year follow-up. Patients were considered non-persistent when there was a gap of ≥180 days after the end of a prescription. Adherence rates were calculated as the proportion of days covered (PDC) for persistent patients. Patients with a PDC

AB - Background: The use of statins as the most extensively used lipid-lowering therapy is known to be suboptimal in daily practice. Few studies, however, have looked at non-adherence and non-persistence as distinct phenomena. Objectives: To evaluate statin adherence and persistence rate, and to identify potential predictors associated with statin non-adherence and non-persistence among patients on oral diabetes medication. Methods: We conducted a cohort study of statin starters using the pharmacy database IADB.nl. We included patients on oral diabetes medication aged 40 years and older at the start of statin treatment between 1994 and 2014. Adherence and persistence rates were measured during a 3-year follow-up. Patients were considered non-persistent when there was a gap of ≥180 days after the end of a prescription. Adherence rates were calculated as the proportion of days covered (PDC) for persistent patients. Patients with a PDC

KW - hydroxymethylglutaryl coenzyme A reductase inhibitor

KW - adult

KW - aged

KW - clinical trial

KW - cohort analysis

KW - diabetes mellitus

KW - drug therapy

KW - female

KW - follow up

KW - hazard ratio

KW - human

KW - major clinical study

KW - male

KW - middle aged

KW - Netherlands

KW - pharmacy

KW - prescription

KW - primary prevention

KW - proportional hazards model

KW - retrospective study

KW - secondary prevention

KW - social status

KW - IADB

U2 - 10.1002/pds.4275

DO - 10.1002/pds.4275

M3 - Meeting Abstract

SN - 1053-8569

VL - 26

SP - 517

EP - 518

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

IS - Supplement 2

M1 - 856

T2 - 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management

Y2 - 25 August 2017 through 30 August 2017

ER -